TY - JOUR
T1 - Elevated serum levels of IL-10 are associated with inferior progression-free survival in patients with Hodgkin's disease treated with radiotherapy
AU - Visco, Carlo
AU - Vassilakopoulos, Theodoros P.
AU - Kliche, Kay Oliver
AU - Nadali, Gianpaolo
AU - Viviani, Simonetta
AU - Bonfante, Valeria
AU - Medeiros, L. Jeffrey
AU - Notti, P.
AU - Rassidakis, George Z.
AU - Peethambaram, Prema
AU - Wilder, Richard
AU - Witzig, Thomas
AU - Gianni, Massimo
AU - Bonadonna, Gianni
AU - Pizzolo, Giovanni
AU - Pangalis, Gerassimos A.
AU - Cabanillas, Fernando
AU - Sarris, Andreas H.
N1 - Funding Information:
We would like to express our appreciation to Offilia Messina for assistance with data collection and Joyce Palmer for assistance with the preparation of the manuscript. This work was supported in part by Cancer Center Support Grant CA-16672 to the University of Texas M.D. Anderson Cancer Center.
PY - 2004/10
Y1 - 2004/10
N2 - Elevated pretreatment serum interleukin-10 (IL-10) is associated with inferior progression-free survival (PFS) in patients with Hodgkin's disease (HD) treated with ABVD or equivalent regimens. Therefore, we explored the association of serum IL-10 with presenting features and PFS in HD patients treated only by radiotherapy (RT) with curative intent. Eligible patients were previously untreated, had biopsy-proven HD, were older than 16 years, HIV-negative, and had unthawed pretreatment serum. Serum IL-10 levels were measured with ELISA and were considered high if ≥ 10 pg/ml. We identified 69 patients with median age of 34 years (range 16-74), of who 52% were males, and 3% had B-symptoms. Ann Arbor Stage was I in 35%, II in 58%, and III in 7% of the patients. Histology was lymphocyte predominance in 26%, and classical HD in 74% of the patients. Serum IL-10 was elevated in 35% of the patients. After a median follow-up of 67 months for survivors, the 5-year PFS of patients with high vs. normal serum IL-10 was 50% vs. 81% (all patients, P = 0.006), and 43% vs. 77% for the subset with classical HD (P = 0.008). Multivariate analysis revealed that high serum IL-10 and β 2-microglobulin were independently associated with inferior PFS. Patients with none, 1, or 2 adverse features comprised 57%, 36%, and 7% of the population, and their 5-year PFS was 80%, 63%, and 0%, respectively (P < 0.0001). In conclusion, high serum IL-10 is independently associated with inferior PFS in patients with HD treated with RT.
AB - Elevated pretreatment serum interleukin-10 (IL-10) is associated with inferior progression-free survival (PFS) in patients with Hodgkin's disease (HD) treated with ABVD or equivalent regimens. Therefore, we explored the association of serum IL-10 with presenting features and PFS in HD patients treated only by radiotherapy (RT) with curative intent. Eligible patients were previously untreated, had biopsy-proven HD, were older than 16 years, HIV-negative, and had unthawed pretreatment serum. Serum IL-10 levels were measured with ELISA and were considered high if ≥ 10 pg/ml. We identified 69 patients with median age of 34 years (range 16-74), of who 52% were males, and 3% had B-symptoms. Ann Arbor Stage was I in 35%, II in 58%, and III in 7% of the patients. Histology was lymphocyte predominance in 26%, and classical HD in 74% of the patients. Serum IL-10 was elevated in 35% of the patients. After a median follow-up of 67 months for survivors, the 5-year PFS of patients with high vs. normal serum IL-10 was 50% vs. 81% (all patients, P = 0.006), and 43% vs. 77% for the subset with classical HD (P = 0.008). Multivariate analysis revealed that high serum IL-10 and β 2-microglobulin were independently associated with inferior PFS. Patients with none, 1, or 2 adverse features comprised 57%, 36%, and 7% of the population, and their 5-year PFS was 80%, 63%, and 0%, respectively (P < 0.0001). In conclusion, high serum IL-10 is independently associated with inferior PFS in patients with HD treated with RT.
KW - Hodgkin's disease
KW - Interleukin-10
KW - Prognostic factors
KW - Radiotherapy
UR - http://www.scopus.com/inward/record.url?scp=4544339987&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=4544339987&partnerID=8YFLogxK
U2 - 10.1080/10428190410001712234
DO - 10.1080/10428190410001712234
M3 - Article
C2 - 15370254
AN - SCOPUS:4544339987
SN - 1042-8194
VL - 45
SP - 2085
EP - 2092
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 10
ER -